Ketamine Metabolite (2 R,6 R)-Hydroxynorketamine Interacts with μ and κ Opioid Receptors
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
values congruous with our simulations. Overall, our findings are consistent with opioid pathway involvement in ketamine function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Sigmoidal dose–response inhibition curves from [35S]GTPγS assays, including standard deviations. Increasing concentrations of HNK depress activation in both MOR and KOR, suggesting an inverse agonist effect. This is attenuated by pretreatment with naltrexone in both MOR and KOR.](https://figures.cochat.ai/paper-figures/93ef94d2282a46cd9d55bd3e7ce349f7/ketamine-metabolite-2-i-r-i-6-i-r-i-hydroxynorketamine-interacts-with-and-opioid-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The effect of (2R,6R)-HNK was blocked by pretreatment with the opioid receptor antagonist naltrexone”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Joseph et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is possible that inverse agonism of μ and κ-opioid receptors may help to restrict the potential for abuse of (2R,6R)-HNK similar to how naltrexone helps prevent relapse in opioid and alcohol use disorders, however this assertion requires further research”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Joseph et al., 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“computational analyses of the predicted interaction between ketamine and its metabolites to the μ and κ-opioid receptor suggested that (2R,6R)-HNK interacted with the orthosteric binding pockets at high affinity (Joseph et al., 2021).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Joseph et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“This study also used G-protein recruitment assays to conclude that (2R,6R)-HNK acts as an inverse agonist, with IC50 values of 0.56 nM and 2.1 x 10−5 nM for the μ and κ-opioid receptor, respectively.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Joseph et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“whereas (2R,6R)-HNK may be an inverse agonist at μ and κ-opioid receptors within antidepressant relevant concentrations, though these findings require replication.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Joseph et al., 2021
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
Scalable molecular dynamics with NAMD
Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kalé, L., & Schulten, K. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20289 · Cited by 16,914 · cited 1×
“All simulations were conducted with NAMD 2.12 or 2.13 molecular dynamics software, 53 using GPUs where possible.”
InfluentialCHARMM‐GUI: A web‐based graphical user interface for CHARMM
Jo, S., Kim, T., Iyer, V. G., & Im, W. (2008) · Journal of Computational Chemistry · doi:10.1002/jcc.20945 · Cited by 9,284
Best, R. B., Zhu, X., Shim, J., Lopes, P. E. M., Mittal, J., Feig, M., & MacKerell, A. D. (2012) · Journal of Chemical Theory and Computation · doi:10.1021/ct300400x · Cited by 4,532
Update of the CHARMM All-Atom Additive Force Field for Lipids: Validation on Six Lipid Types
Klauda, J. B., Venable, R. M., Freites, J. A., O’Connor, J. W., Tobias, D. J., Mondragon-Ramirez, C., Vorobyov, I., MacKerell, A. D., & Pastor, R. W. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp101759q · Cited by 4,501
Crystal structure of the β2 adrenergic receptor–Gs protein complex
Rasmussen, S. G. F., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., et al. (2011) · Nature · doi:10.1038/nature10361 · Cited by 3,009
Automation of the CHARMM General Force Field (CGenFF) I: Bond Perception and Atom Typing
Vanommeslaeghe, K., & MacKerell, A. D. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300363c · Cited by 2,169
ESTIMATION OF PURE-COMPONENT PROPERTIES FROM GROUP-CONTRIBUTIONS
JOBACK, K. G., & REID, R. C. (1987) · Chemical Engineering Communications · doi:10.1080/00986448708960487 · Cited by 1,965
Vanommeslaeghe, K., Raman, E. P., & MacKerell, A. D. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci3003649 · Cited by 1,750
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Structural insights into µ-opioid receptor activation
Huang, W., Manglik, A., Venkatakrishnan, A. J., Laeremans, T., Feinberg, E. N., Sanborn, A. L., Kato, H. E., Livingston, K. E., Thorsen, T. S., Kling, R. C., et al. (2015) · Nature · doi:10.1038/nature14886 · Cited by 885
ModLoop: automated modeling of loops in protein structures
Fiser, A., & Sali, A. (2003) · Bioinformatics · doi:10.1093/bioinformatics/btg362 · Cited by 820
PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome
Kroeze, W. K., Sassano, M. F., Huang, X.-P., Lansu, K., McCorvy, J. D., Giguère, P. M., Sciaky, N., & Roth, B. L. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3014 · Cited by 755
Free Energy of Ionic Hydration
Hummer, G., Pratt, L. R., & García, A. E. (1996) · The Journal of Physical Chemistry · doi:10.1021/jp951011v · Cited by 692
Structure of the µ-opioid receptor–Gi protein complex
Koehl, A., Hu, H., Maeda, S., Zhang, Y., Qu, Q., Paggi, J. M., Latorraca, N. R., Hilger, D., Dawson, R., Matile, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0219-7 · Cited by 658
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Rapid parameterization of small molecules using the force field toolkit
Mayne, C. G., Saam, J., Schulten, K., Tajkhorshid, E., & Gumbart, J. C. (2013) · Journal of Computational Chemistry · doi:10.1002/jcc.23422 · Cited by 518
Crystal Structure of an LSD-Bound Human Serotonin Receptor
Wacker, D., Wang, S., McCorvy, J. D., Betz, R. M., Venkatakrishnan, A. J., Levit, A., Lansu, K., Schools, Z. L., Che, T., Nichols, D. E., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.033 · Cited by 457
Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor
Che, T., Majumdar, S., Zaidi, S. A., Ondachi, P., McCorvy, J. D., Wang, S., Mosier, P. D., Uprety, R., Vardy, E., Krumm, B. E., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.011 · Cited by 365
R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Zhang, J.-C., Li, S.-X., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.033 · Cited by 357
Wang, J., Deng, Y., & Roux, B. (2006) · Biophysical Journal · doi:10.1529/biophysj.106.084301 · Cited by 355
The [35S]GTPγS binding assay: approaches and applications in pharmacology
Harrison, C., & Traynor, J. R. (2003) · Life Sciences · doi:10.1016/j.lfs.2003.07.005 · Cited by 302
Interaction of the Chiral Forms of Ketamine with Opioid, Phencyclidine, σ and Muscarinic Receptors
Hustveit, O., Maurset, A., & Øye, I. (1995) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1995.tb01041.x · Cited by 246
Molecular mechanism of biased signaling in a prototypical G protein–coupled receptor
Suomivuori, C.-M., Latorraca, N. R., Wingler, L. M., Eismann, S., King, M. C., Kleinhenz, A. L. W., Skiba, M. A., Staus, D. P., Kruse, A. C., Lefkowitz, R. J., et al. (2020) · Science · doi:10.1126/science.aaz0326 · Cited by 238
Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro
SMITH, D., BOUCHAL, R., DESANCTIS, C., MONROE, P., AMEDRO, J., PERROTTI, J., & CRISP, T. (1987) · Neuropharmacology · doi:10.1016/0028-3908(87)90084-0 · Cited by 237
Protonation and pK changes in protein–ligand binding
Onufriev, A. V., & Alexov, E. (2013) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583513000024 · Cited by 199
Fukumoto, K., Fogaça, M. V., Liu, R.-J., Duman, C., Kato, T., Li, X.-Y., & Duman, R. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814709116 · Cited by 188
Self-citationAndrade, C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17f11738 · Cited by 178
The interaction of ketamine with the opiate receptor
Smith, D. J., Pekoe, G. M., Martin, L. L., & Coalgate, B. (1980) · Life Sciences · doi:10.1016/0024-3205(80)90285-4 · Cited by 161
Lumsden, E. W., Troppoli, T. A., Myers, S. J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.-H., Schmidt, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816071116 · Cited by 158
Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents
Klein, M. E., Chandra, J., Sheriff, S., & Malinow, R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916570117 · Cited by 156
( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions
Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., Thomas, C. J., Moaddel, R., Zarate, C. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819540116 · Cited by 152
Predicting Binding Affinities for GPCR Ligands Using Free-Energy Perturbation
Lenselink, E. B., Louvel, J., Forti, A. F., van Veldhoven, J. P. D., de Vries, H., Mulder-Krieger, T., McRobb, F. M., Negri, A., Goose, J., Abel, R., et al. (2016) · ACS Omega · doi:10.1021/acsomega.6b00086 · Cited by 142
Potentiation of μ‐opioid receptor‐mediated signaling by ketamine
Gupta, A., Devi, L. A., & Gomes, I. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07361.x · Cited by 132
An Overview of Electrostatic Free Energy Computations for Solutions and Proteins
Lin, Y.-L., Aleksandrov, A., Simonson, T., & Roux, B. (2014) · Journal of Chemical Theory and Computation · doi:10.1021/ct500195p · Cited by 131
Hirota, K., Okawa, H., Appadu, B. L., Grandy, D. K., Devi, L. A., & Lambert, D. G. (1999) · Anesthesiology · doi:10.1097/00000542-199901000-00023 · Cited by 130
AMPA Receptor Activation–Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine
Yang, C., Kobayashi, S., Nakao, K., Dong, C., Han, M., Qu, Y., Ren, Q., Zhang, J.-C., Ma, M., Toki, H., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.05.007 · Cited by 125
Pacheco, D. D. F., Romero, T. R. L., & Duarte, I. D. G. (2014) · Brain Research · doi:10.1016/j.brainres.2014.03.026 · Cited by 122
(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice
Yamaguchi, J.-I., Toki, H., Qu, Y., Yang, C., Koike, H., Hashimoto, K., Mizuno-Yasuhira, A., & Chaki, S. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0084-y · Cited by 105
Novel Molecular Targets of Dezocine and Their Clinical Implications
Liu, R., Huang, X., Yeliseev, A., Jin, X., & Roth, B. L. (2013) · Anesthesiology · doi:10.1097/aln.0000000000000076 · Cited by 103
Self-citationCohen, M. L., & Trevor, A. J. (1974) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29839-1 · Cited by 101
Structure of the Pentameric Ligand-Gated Ion Channel GLIC Bound with Anesthetic Ketamine
Pan, J., Chen, Q., Willenbring, D., Mowrey, D., Kong, X.-P., Cohen, A., Divito, C. B., Xu, Y., & Tang, P. (2012) · Structure · doi:10.1016/j.str.2012.08.009 · Cited by 81
Accurate Prediction of GPCR Ligand Binding Affinity with Free Energy Perturbation
Deflorian, F., Pérez‐Benito, L., Lenselink, E. B., Congreve, M., van Vlijmen, H., Mason, J. S., de Graaf, C., & Tresadern, G. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00449 · Cited by 80
A Unitary Anesthetic Binding Site at High Resolution
Vedula, L. S., Brannigan, G., Economou, N. J., Xi, J., Hall, M. A., Liu, R., Rossi, M. J., Dailey, W. P., Grasty, K. C., Klein, M. L., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.017814 · Cited by 78
Self-citationChemotype-selective Modes of Action of κ-Opioid Receptor Agonists
Vardy, E., Mosier, P. D., Frankowski, K. J., Wu, H., Katritch, V., Westkaemper, R. B., Aubé, J., Stevens, R. C., & Roth, B. L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.515668 · Cited by 71
Yokoyama, R., Higuchi, M., Tanabe, W., Tsukada, S., Naito, M., Yamaguchi, T., Chen, L., Kasai, A., Seiriki, K., Nakazawa, T., et al. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172876 · Cited by 65
Salari, R., Joseph, T., Lohia, R., Hénin, J., & Brannigan, G. (2018) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.8b00447 · Cited by 60
Self-citationIdentification of a fluorescent general anesthetic, 1-aminoanthracene
Butts, C. A., Xi, J., Brannigan, G., Saad, A. A., Venkatachalan, S. P., Pearce, R. A., Klein, M. L., Eckenhoff, R. G., & Dmochowski, I. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810590106 · Cited by 51
Self-citationLigand interaction, binding site and G protein activation of the mu opioid receptor
Cui, X., Yeliseev, A., & Liu, R. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.060 · Cited by 40
Self-citationAzi-isoflurane, a Photolabel Analog of the Commonly Used Inhaled General Anesthetic Isoflurane
Eckenhoff, R. G., Xi, J., Shimaoka, M., Bhattacharji, A., Covarrubias, M., & Dailey, W. P. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn900014m · Cited by 38
Self-citationWoll, K. A., Peng, W., Liang, Q., Zhi, L., Jacobs, J. A., Maciunas, L., Bhanu, N., Garcia, B. A., Covarrubias, M., Loll, P. J., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00222 · Cited by 38
Self-citationConcepts and protocols for electrostatic free energies
Simonson, T., & Roux, B. (2016) · Molecular Simulation · doi:10.1080/08927022.2015.1121544 · Cited by 38
Mafi, A., Kim, S., & Goddard, W. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910006117 · Cited by 37
Regina, A. L., Petrillo, P., Sbacchi, M., & Tavani, A. (1988) · Life Sciences · doi:10.1016/0024-3205(88)90638-8 · Cited by 35
EVIDENCE FOR DIRECT INTERACTION OF KETAMINE WITH α‐ AND β2‐ADRENOCEPTORS
Bevan, R., Rose, M., & Duggan, K. A. (1997) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1997.tb02720.x · Cited by 32
Molecular recognition of ketamine by a subset of olfactory G protein–coupled receptors
Ho, J., Perez‐Aguilar, J. M., Gao, L., Saven, J. G., Matsunami, H., & Eckenhoff, R. G. (2015) · Science Signaling · doi:10.1126/scisignal.2005912 · Cited by 19
Self-citationOakley, S., Vedula, L. S., Bu, W., Meng, Q. C., Jin, X., Liu, R., Eckenhoff, R. G., & Loll, P. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032070 · Cited by 17
Self-citationAzi-medetomidine: Synthesis and Characterization of a Novel α2 Adrenergic Photoaffinity Ligand
McKinstry-Wu, A. R., Woll, K. A., Joseph, T. T., Bu, W., White, E. R., Bhanu, N. V., Garcia, B. A., Brannigan, G. H., Dailey, W. P., & Eckenhoff, R. G. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00484 · Cited by 8
Self-citationKetamine Inhibition of the Pentameric Ligand-Gated Ion Channel GLIC
Ion, B. F., Wells, M. M., Chen, Q., Xu, Y., & Tang, P. S. (2017) · Biophysical Journal · doi:10.1016/j.bpj.2017.06.041 · Cited by 6
Molecular Mechanics Parameterization of Anesthetic Molecules
Joseph, T. T., & Hénin, J. (2018) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2018.01.003 · Cited by 4
Self-citation
Research works printed but not linked: 1
- Cohen M. L., 1974, J. Pharmacol. Exp. Ther., 189, 351
Cited by
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search
Bonaventura, J., Gomez, J. L., Carlton, M. L., Lam, S., Sánchez‐Soto, M., Morris, P. J., Moaddel, R., Kang, H. J., Zanos, P., Gould, T. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01673-w · Cited by 49
Jiang, C. S., Dileone, R., Pittenger, C., & Duman, R. S. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02796-0 · Cited by 50
Alchemical Free Energy Calculations on Membrane-Associated Proteins
Papadourakis, M., Sinenka, H., Matricon, P. G., Hénin, J., Brannigan, G. H., Pérez‐Benito, L., Pande, V., van Vlijmen, H., de Graaf, C., Deflorian, F., et al. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00365 · Cited by 34
Self-citationWulf, H. A., Browne, C. A., Zarate, C. A., & Lucki, I. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06118-4 · Cited by 26
Metadata
- Authors
- Joseph, T. T., Bu, W., Lin, W., Zoubak, L., Yeliseev, A., Liu, R., Eckenhoff, R. G., & Brannigan, G.
- Affiliations
- University of Pennsylvania (US)
- Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
- National Institutes of Health (US)
- Rutgers, The State University of New Jersey (US)
- Corresponding author
- Joseph, Thomas T.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-04-27
- Volume
- 12
- Issue
- 9
- Pages
- 1487-1497
- ISSN
- 1948-7193 (ISSN-L)
- PMC
- PMC8154314
- OpenAlex
- W3157868786
- Cited by
- 28
- References
- 60
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 6 · 2023: 5 · 2022: 5 · 2021: 2
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- ACS Chemical Neuroscience (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Foundation for Anesthesia Education and Research
- National Institute on Alcohol Abuse and Alcoholism
- National Institute of General Medical Sciences (K08GM139031, R01GM111421, T32GM112596)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- ketamine metabolites, (2R,6R)-hydroxynorketamine, mu-opioid receptor, kappa opioid receptor, opioid receptor interaction, molecular docking
- MeSH terms
- Antidepressive Agents, Depression, Ketamine, Receptors, Opioid, kappa
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.